Ashley T. Munchel

TL;DR: Results suggest that mini-haploBMT with post-transplantation Cy is associated with acceptably low toxicities and can provide longterm survival, if not cure, for many patients with advanced hematologic malignancies.

TL;DR: Nonmyeloablative haploidentical stem cell transplantation with post-transplantation cyclophosphamide seems to be a promising, potentially curative, option for patients with hematological malignancies who either lack an HLA-matched related or unrelated donor, or in whom a myeloablatives preparative regimen is contraindicated due to significant co-morbidities or history of extensive pre-treatment.

TL;DR: Clinical cases are used to highlight some of the more common emergent complications after hematopoietic cell transplantation.

TL;DR: A 19-year-old man with no significant medical history noted 3 weeks of right facial numbness and slurred speech, and on examination, he had decreased sensation in the right middle and lower trigeminal nerve distributions, right tongue deviation, and bilateral facial weakness.

TL;DR: Analysis of immune reconstitution in fifty-three consecutive hematologic malignancies patients receiving nonmyeloablative conditioning, T cell-replete, HLA-haploidentical bone marrow transplantation (BMT), and graft versus host disease prophylaxis suggests that PT/Cy selectively preserves pathogen-specific memory T cells necessary to protect against infection.